Multivalent ligand: Design principle for targeted therapeutic delivery approach

Therapeutic Delivery

Volumn 3, Issue 10, 2012, Pages 1171-1187

  Chittasupho, Chuda ^a  

^a SRINAKHARINWIROT UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIBODY CONJUGATE; ARGINYLGLYCYLASPARTIC ACID; CANCER VACCINE; CARBOHYDRATE; CEPHALOSPORIN; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENDRIMER; DOXORUBICIN; LIGAND; MACROGOL; MULTIVALENT LIGAND; NANOPARTICLE; PEPTIDE; POLYAMIDOAMINE; POLYGLACTIN; POLYMER; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4; VITRONECTIN RECEPTOR;

AUTOIMMUNE DISEASE; BINDING AFFINITY; BINDING SITE; BREAST CANCER; CANCER IMMUNOTHERAPY; CONCENTRATION (PARAMETERS); CONFORMATIONAL TRANSITION; CONTROLLED DRUG RELEASE; DENSITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; ENCAPSULATION; ENTHALPY; ENTROPY; HUMAN; IC 50; IMMUNOGENICITY; LIGAND BINDING; MOLECULAR INTERACTION; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN MULTIMERIZATION; REVIEW; T LYMPHOCYTE ACTIVATION; THERMODYNAMICS;

EID: 84867940749     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.99     Document Type: Review

References (142)

1. Kiessling LL, Gestwicki JE, Strong LE. Synthetic multivalent ligands as probes of signal transduction. Angew. Chem. Int. Ed. Engl. 45(15), 2348-2368 (2006
2. Schweitzer-Stenner R, Licht A, Pecht I. Dimerization kinetics of the IgE-class antibodies by divalent haptens. II. The interactions between intact IgE and haptens. Biophys J. 63(2), 563-568 (1992
3. Schweitzer-Stenner R, Licht A, Luscher I, Pecht I. Oligomerization and ring closure of immunoglobulin E class antibodies by divalent haptens. Biochemistry 26(12), 3602-3612 (1987
4. Kitov PI, Paszkiewicz E, Sadowska JM et al. Impact of the nature and size of the polymeric backbone on the ability of heterobifunctional ligands to mediate shiga toxin and serum amyloid p component ternary complex formation. Toxins 3(9), 1065-1088 (2011
5. Stone E, Hirama T, Chen W et al. A novel pentamer versus pentamer approach to generating neutralizers of verotoxin 1. Mol. Immunol. 44(9), 2487-2491 (2007
6. Ewers H, Romer W, Smith AE et al. GM1 structure determines SV40-induced membrane invagination and infection. Nat. Cell Biol. 12(1), 11-18 (2010
7. Ling H, Boodhoo A, Hazes B et al. Structure of the shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. Biochemistry 37(7), 1777-1788 (1998
8. Riedel T, Ghasparian A, Moehle K, Rusert P, Trkola A, Robinson JA. Synthetic virus-like particles and conformationally constrained peptidomimetics in vaccine design. ChemBioChem 12(18), 2829-2836 (2011
9. Luo XM, Lei MY, Feidi RA et al. Dimeric 2G12 as a potent protection against HIV-1. PLoS Pathog. 6(12), e1001225 (2010
10. Staropoli I, Chanel C, Girard M, Altmeyer R. Processing, stability, and receptor binding properties of oligomeric envelope glycoprotein from a primary HIV-1 isolate. J. Biol. Chem. 275(45), 35137-35145 (2000
11. Kiessling LL, Gestwicki JE, Strong LE. Synthetic multivalent ligands in the exploration of cell-surface interactions. Curr. Opin. Chem. Biol. 4(6), 696-703 (2000
12. Gestwicki JE, Cairo CW, Strong LE, Oetjen KA, Kiessling LL. Influencing receptor-ligand binding mechanisms with multivalent ligand architecture. J. Am Chem. Soc. 124(50), 14922-14933 (2002
13. Bertozzi CR, Rabuka D. In: Essentials of Glycobiology (2nd Edition). Structural Basis of Glycan Diversity. Varki A et al. (Eds). Cold Spring Harbor Laboratory Press, NY, USA (2009
14. Pieters RJ. Maximising multivalency effects in proteinYcarbohydrate interactions. Org. Biomol. Chem. 7(10), 2013-2025 (2009
15. Dam TK, Brewer CF. Effects of clustered epitopes in multivalent ligandYreceptor interactions. Biochemistry 47(33), 8470-8476 (2008
16. Mazzaglia A, Forde D, Garozzo D, Malvagna P, Ravoo BJ, Darcy R. Multivalent binding of galactosylated cyclodextrin vesicles to lectin. Org. BioMol. Chem. 2(7), 957-960 (2004
17. Kanai M, Mortell KH, Kiesslingn LL. Varying the size of multivalent ligands. the dependence of concanavalin A binding on neoglycopolymer length. J. Am. Chem. Soc. 119, 9931-9932 (1997
18. Jencks WP. On the attribution and additivity of binding energies. Proc. Natl Acad. Sci USA 78(7), 4046-4050 (1981
19. Fisher BM, Grilley JE, Raines RT. A new remote subsite in ribonuclease A. J. Biol. Chem. 273(51), 34134-34138 (1998
20. De Lean A, Munson PJ, Rodbard D. Multi-subsite receptors for multivalent ligands. Application to drugs, hormones, and neurotransmitters. Mol. Pharmacol. 15(1), 60-70 (1979
21. Leung E, Blom AM, Clemenza L, Isenman DE. The complement regulator C4b-binding protein (C4BP) interacts with both the C4c and C4dg subfragments of the parent C4b ligand. evidence for synergy in C4BP subsite binding. Biochemistry 45(27), 8378-8392 (2006
22. Hlavacek WS, Posner RG, Perelson AS. Steric effects on multivalent ligandYreceptor binding. exclusion of ligand sites by bound cell surface receptors. Biophys J. 76(6), 3031-3043 (1999
23. Mathai Mammen S-KC, Whitesides GM. Polyvalent interactions in biological systems. implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Ed. 37, 2754-2794 (1998
24. Nicola L, Pohl LLK. Scope of multivalent ligand function. lactose-bearing neoglycopolymers by ring-opening metathesis polymerization. Synthesis 1515-1519 (1999
25. Tejler J, Tullberg E, Frejd T, Leffler H, Nilsson UJ. Synthesis of multivalent lactose derivatives by 1,3-dipolar cycloadditions. selective galectin-1 inhibition. Carbohydr. Res. 341(10), 1353-1362 (2006
26. Gestwicki JE, Strong LE, Kiessling LL. Tuning chemotactic responses with synthetic multivalent ligands. Chem. Biol. 7(8), 583-591 (2000
27. Lee RT, Lee YC. Affinity enhancement by multivalent lectinYcarbohydrate interaction. Glycoconj. J. 17(7-9), 543-551 (2000
28. Lindhorst TK. Artificial multivalent sugar ligands to understand and manipulate carbohydrateYprotein interactions. Topics Curr. Chem. 218, 201-232 (2002
29. Kane RS. Thermodynamics of multivalent interactions. influence of the linker. Langmuir 26(11), 8636-8640 (2010
30. Handl HL, Vagner J, Han H, Mash E, Hruby VJ, Gillies RJ. Hitting multiple targets with multimeric ligands. Expert Opin. Ther. Targets 8(6), 565-586 (2004
31. Mulder A, Huskens J, Reinhoudt DN. Multivalency in supramolecular chemistry and nanofabrication. Org. BioMol. Chem. 2(23), 3409-3424 (2004
32. Krishnamurthy VM, Semetey V, Bracher PJ, Shen N, Whitesides GM. Dependence of effective molarity on linker length for an intramolecular proteinYligand system. J. Am. Chem. Soc. 129(5), 1312-1320 (2007
33. Karaman R. The effective molarity (EM) Y a computational approach. Bioorg. Chem. 38(4), 165-172 (2010
34. Huskens J. Multivalent interactions at interfaces. Curr. Opin. Chem. Biol. 10(6), 537-543 (2006
35. Shewmake TA, Solis FJ, Gillies RJ, Caplan MR. Effects of linker length and flexibility on multivalent targeting. Biomacromolecules 9(11), 3057-3064 (2008
36. Gargano JM, Ngo T, Kim JY, Acheson DW, Lees WJ. Multivalent inhibition of AB(5) toxins. J. Am. Chem. Soc. 123(51), 12909-12910 (2001
37. Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat. Biotechnol. 23(11), 1418-1423 (2005
38. Sacchettini JC, Baum LG, Brewer CF. Multivalent proteinYcarbohydrate interactions. A new paradigm for supermolecular assembly and signal transduction. Biochemistry 40(10), 3009-3015 (2001
39. Pluckthun A, Pack P. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 3(2), 83-105 (1997
40. Haywood AM. Virus receptors. binding, adhesion strengthening, and changes in viral structure. J. Virol. 68(1), 1-5 (1994
41. Cuesta AM, Sainz-Pastor N, Bonet J, Oliva B, Alvarez-Vallina L. Multivalent antibodies. when design surpasses evolution. Trends Biotechnol. 28(7), 355-362 (2010
42. Martinez-Veracoechea FJ, Frenkel D. Designing super selectivity in multivalent nano-particle binding. Proc. Natl Acad. Sci. USA 108(27), 10963-10968 (2011
43. Lee RT, Lee YC. Affinity enhancement by multivalent lectin-carbohydrate interaction. Glycoconj, J. 17(7-9), 543-551 (2000
44. Caux C, Zitvogel L. Recent successes of cancer immunotherapy. a new dimension in personalized medicine? Target Oncol. 7(1), 1-2 (2012
45. Santulli-Marotto S, Nair SK, Rusconi C, Sullenger B, Gilboa E. Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res. 63(21), 7483-7489 (2003
46. Kukowska-Latallo JF, Candido KA, Cao Z et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 65(12), 5317-5324 (2005
47. Jin ZH, Furukawa T, Waki A et al. Effect of multimerization of a linear Arg-Gly-Asp peptide on integrin binding affinity and specificity. Biol. Pharm. Bull. 33(3), 370-378 (2010
48. Rosca EV, Stukel JM, Gillies RJ, Vagner J, Caplan MR. Specificity and mobility of biomacromolecular, multivalent constructs for cellular targeting. Biomacromolecules 8(12), 3830-3835 (2007
49. Herrmann SH, Mescher MF. The requirements for antigen multivalency in class I antigen recognition and triggering of primed precursor cytolytic T lymphocytes. J. Immunol. 136(8), 2816-2825 (1986
50. Chittasupho C, Siahaan TJ, Vines CM, Berkland C. Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics. Ther. Deliv 2(7), 873-889 (2011
51. Evans R, Patzak I, Svensson L et al. Integrins in immunity. J. Cell Sci 122(Pt 2), 215-225 (2009
52. Dustin ML, Chakraborty AK, Shaw AS. Understanding the structure and function of the immunological synapse. Cold Spring Harb. Perspect. Biol. 2(10), a002311 (2010
53. Park CG, Thiex NW, Lee KM, Szot GL, Bluestone JA, Lee KD. Targeting and blocking B7 co-stimulatory molecules on antigen-presenting cells using CTLA4Ig-conjugated liposomes. In vitro characterization and in vivo factors affecting biodistribution. Pharm. Res. 20(8), 1239-1248 (2003
54. Tsai HC, Imae T. Fabrication of dendrimers toward biological application. Prog Mol. Biol. Transl Sci 104, 101-140 (2011
55. Khandare J, Calderon M, Dagia NM, Haag R. Multifunctional dendritic polymers in nanomedicine. opportunities and challenges. Chem. Soc. Rev 41(7), 2824-2848 (2012
56. Zong H, Thomas TP, Lee KH et al. Bifunctional PAMAM dendrimer conjugates of folic acid and methotrexate with defined ratio. Biomacromolecules 13(4), 982-991 (2012
57. Wan TC, Tosh DK, Du L, Gizewski ET, Jacobson KA, Auchampach JA. Polyamidoamine (PAMAM) dendrimer conjugate specifically activates the A3 adenosine receptor to improve post-ischemic/ reperfusion function in isolated mouse hearts. BMC Pharmacol. 11, 11 (2011
58. Liu X, Liu C, Laurini E et al. Efficient delivery of sticky siRNA and potent gene silencing in a prostate cancer model using a generation 5 triethanolamine-core PAMAM dendrimer. Mol. Pharm. 9(3), 470-481 (2012
59. Xin G, Zhao X, Duan X et al. Antitumor effect of a generation 4 polyamidoamine dendrimer/cyclooxygenase-2 antisense oligodeoxynucleotide complex on breast cancer in vitro and in vivo. Cancer Biother. Radiopharm. 27(1), 77-87 (2012
60. Hong S, Leroueil PR, Majoros IJ, Orr BG, Baker JR, Jr., Banaszak Holl MM. The binding avidity of a nanoparticle-based multivalent targeted drug-delivery platform. Chem. Biol. 14(1), 107-115 (2007
61. Daftarian P, Kaifer AE, Li W et al. Peptide-conjugated PAMAM dendrimer as a universal DNA vaccine platform to target antigen-presenting cells. Cancer Res. 71(24), 7452-7462 (2011
62. Graf N, Bielenberg DR, Kolishetti N et al. a(V)b(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a pt(IV) prodrug. ACS Nano. 6(5), 4530-4539 (2012
63. Montet X, Funovics M, Montet-Abou K, Weissleder R, Josephson L. Multivalent effects of RGD peptides obtained by nanoparticle display. J. Med. Chem. 49(20), 6087-6093 (2006
64. Kiziltepe T, Ashley JD, Stefanick JF et al. Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo. Blood Cancer J. 2(4), e64 (2012
65. Kirpotin DB, Noble CO, Hayes ME et al. Building and characterizing antibody-targeted lipidic nanotherapeutics. Methods Enzymol. 502, 139-166 (2012
66. Becer CR. The glycopolymer code. synthesis of glycopolymers and multivalent carbohydrateYlectin interactions. Macromol. Rapid Commun. 33(9), 742-752 (2012
67. Cecioni S, Praly JP, Matthews SE, Wimmerova M, Imberty A, Vidal S. Rational design and synthesis of optimized glycoclusters for multivalent lectinY carbohydrate interactions. influence of the linker arm. Chemistry 18(20), 6250-6263 (2012
68. Ogawa Y, Yoshiyama C, Kitaoka T. Helical assembly of azobenzene- conjugated carbohydrate hydrogelators with specific affinity for lectins. Langmuir 28(9), 4404-4412 (2012
69. Tyrrell KL, Citron DM, Warren YA, Goldstein EJ. In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species. Antimicrob. Agents Chemother. 56(4), 2194-2197 (2012
70. Chabre YM, Roy R. Recent trends in glycodendrimer syntheses and applications. Curr. Top. Med. Chem. 8(14), 1237-1285 (2008
71. Clayton R, Hardman J, Labranche CC, Mcreynolds KD. Evaluation of the synthesis of sialic acid-PAMAM glycodendrimers without the use of sugar protecting groups, and the anti-HIV-1 properties of these compounds. Bioconj. Chem. 22(10), 2186-2197 (2011
72. Sebestik J, Niederhafner P, Jezek J. Peptide and glycopeptide dendrimers and analogous dendrimeric structures and their biomedical applications. Amino Acids 40(2), 301-370 (2011
73. Zhang H, Ma Y, Sun XL. Chemically selective liposome surface glyco-functionalization. Methods Mol. Biol. 751, 269-280 (2011
74. Luo SC, Kantchev EA, Zhu B, Siang YW, Yu HH. Tunable, dynamic and electrically stimulated lectin-carbohydrate recognition on a glycan-grafted conjugated polymer. Chem. Commun. 48(55), 6942-6944 (2012
75. Wang Q, Zhou Z, Tang S, Guo Z. CarbohydrateYmonophosphoryl lipid a conjugates are fully synthetic self-adjuvanting cancer vaccines eliciting robust immune responses in the mouse. ACS Chem. Biol. 7(1), 235-240 (2012
76. Govindan SV, Goldenberg DM. Designing immunoconjugates for cancer therapy. Expert Opin. Biol. Ther. 12(7), 873-890 (2012
77. Litvak-Greenfeld D, Benhar I. Risks and untoward toxicities of antibody-based immunoconjugates. Adv. Drug Deliv. Rev. (2012
78. Pasquetto MV, Vecchia L, Covini D, Digilio R, Scotti C. Targeted drug delivery using immunoconjugates: Principles and applications. J. Immunother. 34(9), 611-628 (2011
79. Ogura M, Hatake K, Ando K et al. Phase I study of anti-CD22 immunoconjugate notuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Sci. 103(5), 933-938 (2012
80. Dillman RO. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J. Clin. Oncol. 20(16), 3545-3557 (2002
81. Johnson RN, Kopeckova P, Kopecek J. Synthesis and evaluation of multivalent branched HPMA copolymer-fab́ conjugates targeted to the B-Cell antigen CD20. Bioconj. Chem. 20(1), 129-137 (2009
82. Sharkey RM, Rossi EA, Chang CH, Goldenberg DM. Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies. Cancer Biother. Radio. 25(1), 1-12 (2010
83. Kelly MP, Lee FT, Tahtis K et al. Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct. Cancer Biother. Radio. 23(4), 411-423 (2008
84. Rizvi S, Allen B, Lee C et al. Orthotopic administration of (213)Bi-bevacizumab inhibits progression of PC3 xenografts in the prostate. Immunotherapy 4(5), 549-554 (2012
85. Fanale MA, Forero-Torres A, Rosenblatt JD et al. A Phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin. Cancer Res. 18(1), 248-255 (2012
86. Schindler J, Gajavelli S, Ravandi F et al. A Phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia. Brit. J. Haematol. 154(4), 471-476 (2011
87. Sharkey RM, Rossi EA, Chang CH, Goldenberg DM. Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies. Cancer Biother. Radiopharm. 25(1), 1-12 (2010
88. Cuesta AM, Sanchez-Martin D, Blanco- Toribio A et al. Improved stability of multivalent antibodies containing the human collagen XV trimerization domain. MAbs 4(2), 226-232 (2012
89. Gonzalez GP, Garcia IG, Gonzalez JG et al. Phase I clinical trial of the I-131-labeled anticarcinoembryonic antigen CIGB-M3 multivalent antibody fragment. Cancer Biother. Radio. 26(3), 353-363 (2011
90. Dower SK, Titus JA, Delisi C, Segal DM. Mechanism of binding of multivalent immune complexes to Fc receptors. 2. Kinetics of binding. Biochemistry 20(22), 6335-6340 (1981
91. Defrees SA,, Philips L, Guo L, Zalipsky S. Sialyl lewis × liposomes as a multivalent ligand and inhibitor of E-selectin mediated cellular adhesion. J. Am. Chem. Soc. 118, 6101-6104 (1996
92. Papp I, Sieben C, Sisson AL et al. Inhibition of influenza virus activity by multivalent glycoarchitectures with matched sizes. ChemBioChem. 12(6), 887-895 (2011
93. Nasr K, Pannier N, Frangioni JV, Maison W. Rigid multivalent scaffolds based on adamantane. J. Org. Chem. 73(3), 1056-1060 (2008
94. Adeli M, Kalantari M, Zarnega Z, Kabiri R. Cyclodextrin-based dendritic supramolecules; new multivalent nanocarriers. Rsc Adv. 2(7), 2756-2758 (2012
95. Sansone F, Baldini L, Casnati A, Ungaro R. Calixarenes. from biomimetic receptors to multivalent ligands for biomolecular recognition. New J. Chem. 34(12), 2715-2728 (2010
96. Hlavacek WS, Posner RG, Perelson AS. Steric effects on multivalent ligandYreceptor binding. exclusion of ligand sites by bound cell surface receptors. Biophys J. 76(6), 3031-3043 (1999
97. Cairo CW, Gestwicki JE, Kanai M, Kiessling LL. Control of multivalent interactions by binding epitope density. J. Am. Chem. Soc. 124(8), 1615-1619 (2002
98. David A. Mann MK, Maly DJ, Laura L. Kiessling. Probing low affinity and multivalent interactions with surface plasmon resonance. ligands for concanavalin A. J. Am. Chem. Soc. 120, 10575-10582 (1998
99. Muller KM, Arndt KM, Pluckthun A. Model and simulation of multivalent binding to fixed ligands. Anal. Biochem. 261(2), 149-158 (1998
100. Bandyopadhyay A, Fine RL, Demento S, Bockenstedt LK, Fahmy TM. The impact of nanoparticle ligand density on dendritic-cell targeted vaccines. Biomaterials 32(11), 3094-3105 (2011
101. Hsu CL, Chang HT, Chen CT, Wei SC, Shiang YC, Huang CC. Highly efficient control of thrombin activity by multivalent nanoparticles. Chemistry 17(39), 10994-11000 (2011
102. Mallikaratchy PR, Ruggiero A, Gardner JR et al. A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia. Nucleic Acids Res. 39(6), 2458-2469 (2011
103. Shiokawa T, Hattori Y, Kawano K et al. Effect of polyethylene glycol linker chain length of folate-linked microemulsions loading aclacinomycin A on targeting ability and antitumor effect in vitro and in vivo. Clin. Cancer Res. 11(5), 2018-2025 (2005
104. Arnold M, Cavalcanti-Adam EA, Glass R et al. Activation of integrin function by nanopatterned adhesive interfaces. ChemPhysChem. 5(3), 383-388 (2004
105. Wong RL, Liu B, Zhu X et al. Interleukin-15: Interleukin-15 receptor alpha scaffold for creation of multivalent targeted immune molecules. Protein Eng. Des. Sel. 24(4), 373-383 (2011
106. Lindhagen-Persson M, Brannstrom K, Vestling M, Steinitz M, Olofsson A. Amyloid-beta oligomer specificity mediated by the IgM isotype-implications for a specific protective mechanism exerted by endogenous auto-antibodies. Plos One 5(11), e13928 (2010
107. Schneck JP, Slansky JE, O'herrin SM, Greten TF. Monitoring antigen-specific T-cells using MHC-Ig dimers. Curr. Protoc. Immunol. 17, 12 (2001
108. Zuckier LS, Berkowitz EZ, Sattenberg RJ, Zhao QH, Deng HF, Scharff MD. Influence of affinity and antigen density on antibody localization in a modifiable tumor targeting model. Cancer Res. 60(24), 7008-7013 (2000
109. Charles CH, Luo GX, Kohlstaedt LA et al. Prevention of human rhinovirus infection by multivalent FAB molecules directed against ICAM-1. Antimicrob. Agents Chemother. 47(5), 1503-1508 (2003
110. Lesley J, Hascall VC, Tammi M, Hyman R. Hyaluronan binding by cell surface CD44. J. Biol. Chem. 275(35), 26967-26975 (2000
111. Carlson CB, Mowery P, Owen RM, Dykhuizen EC, Kiessling LL. Selective tumor cell targeting using low-affinity, multivalent interactions. ACS Chem. Biol. 2(2), 119-127 (2007
112. Dustin ML, Olive D, Springer TA. Correlation of CD2 binding and functional properties of multimeric and monomeric lymphocyte function-associated antigen 3. J. Exp Med. 169(2), 503-517 (1989
113. Voulgaraki D, Mitnacht-Kraus R, Letarte M, Foster-Cuevas M, Brown MH, Barclay AN. Multivalent recombinant proteins for probing functions of leucocyte surface proteins such as the CD200 receptor. Immunology 115(3), 337-346 (2005
114. Hutchins BM, Kazane SA, Staflin K et al. Site-specific coupling and sterically controlled formation of multimeric antibody fab fragments with unnatural amino acids. J. Mol. Biol. 406(4), 595-603 (2011
115. Gonzalez GP, Garcia IG, Gonzalez JG et al. Phase I clinical trial of the (131)I-labeled anticarcinoembryonic antigen CIGB-M3 multivalent antibody fragment. Cancer Biother. Radiopharm. 26(3), 353-363 (2011
116. Hultberg A, Temperton NJ, Rosseels V et al. Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules. Plos One 6(4), e17665 (2011
117. Tassa C, Duffner JL, Lewis TA et al. Binding affinity and kinetic analysis of targeted small molecule-modified nanoparticles. Bioconjug. Chem. 21(1), 14-19 (2010
118. Bottini M, D'annibale F, Magrini A et al. Quantum dot-doped silica nanoparticles as probes for targeting of T-lymphocytes. Int. J. Nanomed. 2(2), 227-233 (2007
119. Terskikh AV, Le Doussal JM, Crameri R, Fisch I, Mach JP, Kajava AV. "Peptabody" a new type of high avidity binding protein. Proc. Natl Acad. Sci. USA 94(5), 1663-1668 (1997
120. Welder CA, Lee DH, Takei F. Inhibition of cell adhesion by microspheres coated with recombinant soluble intercellular adhesion molecule-1. J. Immunol. 150(6), 2203-2210 (1993
121. Kim JS, Valencia CA, Liu R, Lin W. Highly-efficient purification of native polyhistidine-tagged proteins by multivalent NTA-modified magnetic nanoparticles. Bioconjug. Chem. 18(2), 333-341 (2007
122. Chen T, Shukoor MI, Wang R et al. Smart multifunctional nanostructure for targeted cancer chemotherapy and magnetic resonance imaging. ACS Nano. 5(10), 7866-7873 (2011
123. Huang YJ, Shiau AL, Chen SY et al. Multivalent structure of galectin-1-nanogold complex serves as potential therapeutics for rheumatoid arthritis by enhancing receptor clustering. Eur. Cell. Mater. 23, 170-181 (2012
124. Truscott SM, Lybarger L, Martinko JM et al. Disulfide bond engineering to trap peptides in the MHC class I binding groove. J. Immunol. 178(10), 6280-6289 (2007
125. Lairmore MD, Digeorge AM, Conrad SF, Trevino AV, Lal RB, Kaumaya PT. Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction. J. Virol. 69(10), 6077-6089 (1995
126. Mcnamara JO, Kolonias D, Pastor F et al. Multivalent 4-1BB binding aptamers costimulate CD8+ T-cells and inhibit tumor growth in mice. J. Clin Invest. 118(1), 376-386 (2008
127. Pampori N, Hato T, Stupack DG et al. Mechanisms and consequences of affinity modulation of integrin avb3 detected with a novel patch-engineered monovalent ligand. J. Biol. Chem. 274(31), 21609-21616 (1999
128. Ding H, Prodinger WM, Kopecek J. Identification of CD21-binding peptides with phage display and investigation of binding properties of HPMA copolymer-peptide conjugates. Bioconjug. Chem. 17(2), 514-523 (2006
129. Puffer EB, Pontrello JK, Hollenbeck JJ, Kink JA, Kiessling LL. Activating B-cell signaling with defined multivalent ligands. ACS Chem. Biol. 2(4), 252-262 (2007
130. Gestwicki JE, Strong LE, Cairo CW, Boehm FJ, Kiessling LL. Cell aggregation by scaffolded receptor clusters. Chem. Biol. 9(2), 163-169 (2002
131. Mowery P, Yang ZQ, Gordon EJ et al. Synthetic glycoprotein mimics inhibit l-selectin-mediated rolling and promote l-selectin shedding. Chem. Biol. 11(5), 725-732 (2004
132. Johnson RN, Kopeckova P, Kopecek J. Synthesis and evaluation of multivalent branched HPMA copolymer-Fab' conjugates targeted to the B-cell antigen CD20. Bioconjug. Chem. 20(1), 129-137 (2009
133. Siliciano RF, Keegan AD, Dintzis RZ, Dintzis HM, Shin HS. The interaction of nominal antigen with T-cell antigen receptors. I. Specific binding of multivalent nominal antigen to cytolytic T-cell clones. J. Immunol. 135(2), 906-914 (1985
134. Helms BA, Reulen SW, Nijhuis S, De Graaf-Heuvelmans PT, Merkx M, Meijer EW. High-affinity peptide-based collagen targeting using synthetic phage mimics: From phage display to dendrimer display. J. Am Chem. Soc. 131(33), 11683-11685 (2009
135. Mcnerny DQ, Kukowska-Latallo JF, Mullen DG et al. RGD dendron bodies; synthetic avidity agents with defined and potentially interchangeable effector sites that can substitute for antibodies. Bioconjug. Chem. 20(10), 1853-1859 (2009
136. Boswell CA, Eck PK, Regino CA et al. Synthesis, characterization, and biological evaluation of integrin avb3-targeted PAMAM dendrimers. Mol. Pharm. 5(4), 527-539 (2008
137. Kim Y, Hechler B, Gao ZG, Gachet C, Jacobson KA. PEGylated dendritic unimolecular micelles as versatile carriers for ligands of G protein-coupled receptors. Bioconjug. Chem. 20(10), 1888-1898 (2009
138. Boswell CA, Eck PK, Regino CA et al. Synthesis, characterization, and biological evaluation of integrin avb3-targeted PAMAM dendrimers. Mol. Pharm. 5(4), 527-539 (2008
139. Wolfenden ML, Cloninger MJ. Carbohydrate-functionalized dendrimers to investigate the predictable tunability of multivalent interactions. Bioconjug Chem. 17(4), 958-966 (2006
140. Euzen R, Reymond JL. Synthesis of glycopeptide dendrimers, dimerization and affinity for Concanavalin A. Bioorg. Med. Chem. 19(9), 2879-2887 (2011
141. Wan TC, Tosh DK, Du L, Gizewski ET, Jacobson KA, Auchampach JA. Polyamidoamine (PAMAM) dendrimer conjugate specifically activates the A3 adenosine receptor to improve post-ischemic/reperfusion function in isolated mouse hearts. BMC Pharm. 11, 11 (2011
142. Chamorro C, Boerman MA, Arnusch CJ, Breukink E, Pieters RJ. Enhancing membrane disruption by targeting and multivalent presentation of antimicrobial peptides. Biochim. Biophys. Acta 1818(9), 2171-2174 (2012